EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

Nandita Nadig, Adarsh Bhimraj iD, Kelly Cawcutt, Kathleen Chiotos iD, Amy L Dzierba, Arthur Y Kim, Greg S Martin iD, Jeffrey C Pearson, Amy Hirsch Shumaker, Lindsey R Baden, Roger Bedimo iD, Vincent Chi-Chung Cheng und 19 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf681 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Nandita Nadig und 30 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Azetidines, Pyrazoles, Purines. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Infectious Diseases Society of America, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article provides a focused update to the clinical practice guideline on the treatment and management of patients with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents a new recommendation on the use of baricitinib vs. tocilizumab in hospitalized adults with severe or critical COVID-19. The panel has previously issued recommendations on baricitinib vs. no baricitinib and tocilizumab vs. no tocilizumab, but this new recommendation compares baricitinib to tocilizumab when the decision has been made to give one or the other. The new recommendation does not address combinations of multiple immunomodulatory agents (ie, baricitinib, tocilizumab, abatacept, infliximab). The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAzetidinesPyrazolesPurinesSulfonamidesCOVID-19 Drug TreatmentAntiviral AgentsHumansSARS-CoV-2COVID-19

Stichwörter der Autor:innen

COVID-19SARS-CoV-2baricitinibguidelinetocilizumab

Substanzen

baricitinibAntibodies, Monoclonal, HumanizedtocilizumabAzetidinesPyrazolesPurinesSulfonamidesAntiviral Agents

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Medicine, New York University Grossman School of Medicine, New York City, New York, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Adarsh Bhimraj, Kathleen Chiotos, Greg S Martin, Roger Bedimo, Kara W Chew, Eric S Daar, Laura Riley, Shmuel Shoham, Pablo Tebas, Zachary Willis, Joshua Wolf

Förderung

  • Infectious Diseases Society of America
  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Nadig, N., Bhimraj, A., Cawcutt, K., Chiotos, K., Dzierba, A. L., Kim, A. Y., Martin, G. S., Pearson, J. C., Shumaker, A. H., Baden, L. R., Bedimo, R., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Hardy, E. J., Johnson, S., MacBrayne, C., Nakamura, M. M., …, & Gandhi, R. T. (2026). 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf681

Vancouver

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf681

BibTeX
@article{Nadig2026,
  author = {Nadig, Nandita and Bhimraj, Adarsh and Cawcutt, Kelly and Chiotos, Kathleen and Dzierba, Amy L and Kim, Arthur Y and Martin, Greg S and Pearson, Jeffrey C and Shumaker, Amy Hirsch and Baden, Lindsey R and Bedimo, Roger and Cheng, Vincent Chi-Chung and Chew, Kara W and Daar, Eric S and Glidden, David V and Hardy, Erica J and Johnson, Steven and MacBrayne, Christine and Nakamura, Mari M and Oliveira, Carlos R and Riley, Laura and Shafer, Robert W and Shoham, Shmuel and Tebas, Pablo and Tien, Phyllis C and Willis, Zachary and Wolf, Joshua and Loveless, Jennifer and Falck-Ytter, Yngve and Morgan, Rebecca L and Gandhi, Rajesh T},
  title = {2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf681}
}
Kostenlos starten →